Zynex Inc. (OTCMKTS:ZYXI) CEO Thomas Sandgaard sold 131,260 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $10.58, for a total transaction of $1,388,730.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Thomas Sandgaard also recently made the following trade(s):
- On Monday, June 10th, Thomas Sandgaard sold 50,000 shares of Zynex stock. The stock was sold at an average price of $8.88, for a total transaction of $444,000.00.
- On Thursday, June 6th, Thomas Sandgaard sold 35,868 shares of Zynex stock. The stock was sold at an average price of $8.00, for a total transaction of $286,944.00.
- On Tuesday, May 21st, Thomas Sandgaard sold 9,045 shares of Zynex stock. The stock was sold at an average price of $8.00, for a total transaction of $72,360.00.
Shares of ZYXI traded down $0.33 during mid-day trading on Monday, hitting $10.29. The company’s stock had a trading volume of 586,207 shares, compared to its average volume of 183,133. The firm has a 50-day moving average price of $8.72 and a 200 day moving average price of $6.80. The stock has a market capitalization of $335.29 million, a price-to-earnings ratio of 46.77 and a beta of 1.05. Zynex Inc. has a fifty-two week low of $2.46 and a fifty-two week high of $11.75.
Zynex (OTCMKTS:ZYXI) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.06. The company had revenue of $10.30 million for the quarter, compared to analysts’ expectations of $9.84 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. Equities research analysts forecast that Zynex Inc. will post 0.28 EPS for the current fiscal year.
Several equities analysts have recently issued reports on the stock. B. Riley lifted their price objective on shares of Zynex from $9.00 to $10.75 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Zacks Investment Research raised shares of Zynex from a “sell” rating to a “hold” rating in a research note on Thursday, June 27th.
Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. purchased a new position in shares of Zynex in the second quarter worth approximately $8,257,000. BlackRock Inc. purchased a new position in shares of Zynex in the second quarter worth approximately $6,957,000. Northern Trust Corp purchased a new position in shares of Zynex in the second quarter worth approximately $627,000. Acadian Asset Management LLC increased its position in shares of Zynex by 127.6% in the second quarter. Acadian Asset Management LLC now owns 108,737 shares of the company’s stock worth $978,000 after acquiring an additional 60,960 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Zynex in the second quarter worth approximately $304,000. 0.05% of the stock is currently owned by institutional investors.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Featured Story: Bond
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.